

Amendments to the Claim:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A peptide having a sequence of at most 44 amino acid residues comprising a motif of the formula

$X^1-X^2\text{-Cys-}X^3\text{-}X^4\text{-}X^5\text{-}X^6\text{-}X^7\text{-}X^8\text{-}X^9\text{-}X^{10}\text{-}X^{11}\text{-}X^{12}\text{-}X^{13}\text{-}X^{14}\text{-}X^{15}\text{-}X^{16}\text{-}X^{17}\text{-Cys-}X^{18}\text{-}X^{19}$,

wherein

(1) each of X^1 and X^{19} is, independently, either a sequence consisting of 2-5 amino acid residues or a single amino acid residue, and

(2) each of $X^2\text{-}X^{18}$ is, independently, a single amino acid residue, and

wherein

X^1 is a sequence consisting of 2-5 amino acid residues, or an amino acid residue selected from Group 2;

X^2 is selected from Group 5;

X^3 , X^{15} and X^4 are selected from Group 1;

X^5 is Thr or selected from Group 1;

X^6 , X^{11} , X^{12} , X^{13} and X^7 are selected from Group 3;

X^8 and X^{17} are selected from Group 1, 3 or 4;

X^9 is selected from Group 5;

X^{10} is selected from Group 2, 3 or 4;

X^{14} is Ser or selected from Group 3;

X^{16} and X^{18} is selected from Group 1 or 3;

X^{19} is a sequence consisting of 2-5 amino acid residues, or a single amino acid residue selected from Group 5;

with Group 1 consisting of Ala, Gly, and Ser,

Group 2 consisting of Arg and Lys,

Group 3 consisting of His, Ile, Leu, Met, Phe, Pro, Thr, Val, Trp, and Tyr,

Group 4 consisting of Asn and Gln , and
Group 5 consisting of Ala, Asn, Arg, Gln, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val;
with the proviso, that when X¹ includes Pro, then X¹⁹ is Gln, and
wherein at least one of the following conditions applies:

- (a) X¹⁹ is Arg or Ala,
- (b) X⁹ is Pro, Arg, or Gln,
- (c) X¹⁹ is Gln and X¹ includes Pro,
- (d) X¹⁹ is 2-5 amino acid residues, or
- (e) X¹⁰ is Asn or Gln.

2-26. (Cancelled)

27. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRHFCGGALIHARFVMTAASCFR (SEQ ID NO: 595).

28. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCGGALIHARFVMTAASCFR (SEQ ID NO: 596).

29. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRHFCGGALIHPRFVMTAASCFR (SEQ ID NO: 597).

30. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCGGALIHPRFVMTAASCFR (SEQ ID NO: 598).

31. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence RFCSAATLVFRPHVLGACFPRGQK (SEQ ID NO: 599).

32. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence NQGRPFCAGALVHPRFVLTAASCFR (SEQ ID NO: 600).

33. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPRFVLTAASCFQ (SEQ ID NO: 601).

34. (Previously Presented) The peptide according to claim

1, wherein said peptide has the sequence NQGRPFCAGALVHPRFVLTAASCFQ (SEQ ID NO: 602).

35. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPQFVLTAASCFR (SEQ ID NO: 603).

36. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence LRGGHFCGATLIAPNFVMSAAHCVA (SEQ ID NO: 604).

37. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence RRGGHFCGATLIARNFVMSAVHCVN (SEQ ID NO: 605).

38. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence RSREYRCGGTLVSQRYILTAASCAA (SEQ ID NO: 606).

39. (Cancelled)

40. (Previously Presented) The peptide according to claim 1, wherein said peptide has the sequence KQGRPFCAGALVHPRFVLTAASCFR (SEQ ID NO: 593).

41-52. (Cancelled)

53. (Previously Presented) The peptide according to claim 1, wherein said peptide is capable of inhibiting the secretion of cytokine IL-6 from monocytes.

54. (Withdrawn) The peptide according to claim 1, wherein said peptide is capable of stimulating the secretion of cytokine IL-6 from monocytes.

55-56. (Cancelled)

57. (Withdrawn) A method of treatment of gram-negative bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 1.

58. (Withdrawn) A method of treatment of gram-positive bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 1.

59-72. (Cancelled)

73. (Previously Presented) A pharmaceutical composition comprising a peptide as defined in claim 1.

74. (Currently Amended) The peptide according to claim 1, wherein at least one of conditions (aa)-(dd) applies

(aa) X19 is Arg,

(bb) ~~X19~~ X9 is Pro,

(cc) X19 is Gln and X1 includes Pro, or

(dd) X19 is 2-5 amino acid residues.

75. (Previously Presented) The peptide according to claim 1, wherein at least one of conditions (aa)-(cc) applies.

76. (Previously Presented) The peptide according to claim 1, wherein at least condition (aa) applies.

77. (Previously Presented) The peptide according to claim 1, wherein at least condition (bb) applies.

78. (Previously Presented) The peptide according to claim 1, wherein at least condition (cc) applies.

79. (Previously Presented) The peptide according to claim 1 wherein X10 is Asn or Gln.

80. (Withdrawn) A method of treatment of gram-negative bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 75.

81. (Withdrawn) A method of treatment of gram-negative bacterial infection comprising administering, to an individual in need, one or more peptides as defined in claim 27.